Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
5000 participants
OBSERVATIONAL
2017-10-01
2040-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Relating Genetic and Environmental Risk Scores to Multiple Sclerosis Susceptibility
NCT01617395
Mechanisms of Disease Severity in Multiple Sclerosis: an Integrative Multimodal Study
NCT03369106
Biomarkers in Multiple Sclerosis
NCT00325988
MS Mosaic: A Longitudinal Research Study on Multiple Sclerosis
NCT02845635
From Genetics to Transcriptomics to Unravel the Mechanisms Behind a Poor Outcome in Multiple Sclerosis
NCT04873492
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This large research study will ultimately enroll 5000 subjects who are at risk of developing MS.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Received anti-TNFa therapy
Received anti-TNFa therapy
No interventions assigned to this group
First-degree relative of MS patients
First-degree relative (child, parent or sibling) of a diagnosed MS patient
A subgroup will be asked to undergo magnetic resonance imaging (MRI). Participants may be asked to donate a stool sample for gut flora analysis and a blood sample for ribonucleic acid (RNA) sequencing.
No interventions assigned to this group
Referred by the Partners MS Center
Referred by the Partners MS Center
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who have received anti-TNFa therapy as treatment for inflammatory diseases other than MS such as Crohn's disease, psoriasis and rheumatoid arthritis, or
* Patients that have been referred for an evaluation of first presentation of neurologic symptoms but do not have a diagnosis of MS
* Live in the United States
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Pittsburgh
OTHER
Brigham and Women's Hospital
OTHER
Columbia University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Philip De Jager
Professor of Neurology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Zongqi Xia, MD, PhD
Role: STUDY_DIRECTOR
University of Pittsburgh
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Institute of Neurological Disorders and Stroke
Bethesda, Maryland, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Brigham and Women's Hospital
Boston, Massachusetts, United States
Columbia University Irving Center
New York, New York, United States
University of Pittsburgh
Pittsburgh, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Xia Z, Steele SU, Bakshi A, Clarkson SR, White CC, Schindler MK, Nair G, Dewey BE, Price LR, Ohayon J, Chibnik LB, Cortese IC, De Jager PL, Reich DS. Assessment of Early Evidence of Multiple Sclerosis in a Prospective Study of Asymptomatic High-Risk Family Members. JAMA Neurol. 2017 Mar 1;74(3):293-300. doi: 10.1001/jamaneurol.2016.5056.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AAAR4456
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.